Efficacy and Tolerability of Capecitabine with Weekly Paclitaxel for Patients with Metastatic Breast Cancer: A Phase II Report of the SAKK

Publisher： Karger

E-ISSN： 1423-0232|71|1-2|54-60

ISSN： 0030-2414

Source： Oncology, Vol.71, Iss.1-2, 2007-04, pp. : 54-60

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II Study of an ‘All-Oral’ Regimen of Capecitabine, Idarubicin and Cyclophosphamide for Metastatic Breast Cancer – Safety, Efficacy and Quality of Life

By  

Oncology, Vol. 68, Iss. 4-6, 2005-08 ,pp. : 520-525

Karger

Access to resources Recommend Favorite

Weekly Docetaxel with or without Gemcitabine as Second-Line Chemotherapy in Paclitaxel-Pretreated Patients with Metastatic Breast Cancer: A Randomized Phase II Study Conducted by the Hellenic Co-Operative Oncology Group

By  

Oncology, Vol. 77, Iss. 3-4, 2009-09 ,pp. : 212-216

Karger

Access to resources Recommend Favorite

Capecitabine with Weekly Paclitaxel for Advanced Breast Cancer: A Phase I Dose-Finding Trial

By  

Oncology, Vol. 67, Iss. 2, 2004-10 ,pp. : 117-122

Karger

Access to resources Recommend Favorite

Weekly Docetaxel in Pretreated Metastatic Breast Cancer Patients: A Phase I-II Study

By  

Oncology, Vol. 68, Iss. 4-6, 2005-08 ,pp. : 356-363

Karger

Access to resources Recommend Favorite

Phase I/II Study of Paclitaxel and 5-Fluorouracil as Second-Line Therapy in Patients with Metastatic Breast Cancer

By  

Oncology Research and Treatment, Vol. 21, Iss. 4, 1998-09 ,pp. : 305-308

Karger

Access to resources Recommend Favorite